Physician profile
Paul A Schmidt
NPI 1073516704
$4,610.99
in general payments reported to CMS, 2019-2025
36 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $124 · 2021: $507 · 2022: $653 · 2023: $989 · 2024: $1,265 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,957 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,956.87 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,054.58 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Supernus Pharmaceuticals, INC. | $599.05 | 2021-2025 | Qelbree, Qelbree, Xyosted |
| Astrazeneca Pharmaceuticals LP | $394.32 | 2019-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $279.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $264.32 | 2020-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $261.29 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $199.06 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $182.30 | 2022-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.88 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $133.73 | 2019 | |
| Pfizer INC. | $93.41 | 2020-2025 | |
| Axsome Therapeutics, INC. | $87.87 | 2024-2025 | Auvelity |
| Abbott Laboratories | $83.81 | 2021-2025 | Freestyle Libre |
| Glaxosmithkline, LLC. | $83.33 | 2023 | Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $67.34 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $62.39 | 2019-2021 | |
| Astellas Pharma US INC | $57.03 | 2024 | Veozah |
| Antares Pharma, INC. | $55.65 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceuticals, INC. | $55.40 | 2020-2021 | |
| Dexcom, INC. | $43.31 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $40.90 | 2023-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.90 | 2021-2022 | |
| Eisai INC. | $38.60 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.30 | 2019-2025 | Vaxneuvance, M-M-R II, Enflonsia |
| Corium, LLC | $28.42 | 2024 | Azstarys |
| Alfasigma USA, INC. | $26.39 | 2021 | |
| Ibsa Pharma INC. | $24.99 | 2024 | Licart, Tirosint, Flector |
| Mycovia Pharmaceuticals, INC. | $23.71 | 2022 | |
| Ardelyx, INC. | $22.06 | 2025 | Ibsrela |
| Noven Therapeutics, LLC | $21.57 | 2024 | Xelstrym |
| Tris Pharma INC | $19.84 | 2023 | Dyanavel Xr |
| Halozyme INC | $18.39 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.30 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.70 | 2022 | |
| Ethicon US, LLC | $14.97 | 2021 | |
| Currax Pharmaceuticals LLC | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.